Dwight Evans, Democrat of Pennsylvania's 3rd district, is making the rounds in financial news this week after disclosures showed him selling shares of General Dynamics and Intel Corporation. Fair enough. But pull back one click and the story gets more interesting: Evans has now filed 4 disclosed trades in the last 90 days, every single one a sale, across four different tickers. His scored trading record across all 8 evaluated positions sits at 0 wins, 8 losses, and a mean 30-day alpha of negative 5.7 percent against the S&P 500. That's a philosophy.
What Got Him in the News
Investing.com flagged the disclosures in the last 24 hours: Evans sold General Dynamics and Intel Corporation, both in the $1,000 to $15,000 range. That's the story as it's been reported. Standard STOCK Act disclosure item. What that coverage doesn't do is zoom out to the rest of his filing history, which is where things get genuinely weird.
Social buzz is minimal and, candidly, misdirected. The Bluesky conversation about "Dwight Evans" this week is mostly about the former Red Sox outfielder who hit for the cycle in 1984. The congressman from Philadelphia is, for now, living in the other Dwight Evans's shadow on the timeline. That will probably change if anyone looks at the actual alpha numbers.
Four Sales in 90 Days. Zero Buys.
Here's what Evans's full disclosure record on Blind Trust shows for the last 90 days:
- May 7, 2026: Sale, Intel Corporation (INTC), $1K-$15K
- May 7, 2026: Sale, Quanta Services (PWR), $1K-$15K
- May 7, 2026: Sale, Thermo Fisher Scientific (TMO), $1K-$15K
- May 11, 2026: Sale, American Tower (AMT), $1K-$15K
Three of those four hit on the same day. All four are sales. No purchases, no holds added, no new positions opened. Whatever Evans is doing with his portfolio right now, he is getting out.
The amounts are modest. The $1,000-to-$15,000 disclosure bracket is the smallest tier the STOCK Act requires, so we're not talking about a member clearing a beach house. But the pattern across all eight scored trades is still the pattern.
The Alpha Record Is Not Good
Blind Trust scores trades by comparing the 30-day post-trade return of each position against the S&P 500 over the same window. A positive alpha means the trade beat the index. A negative alpha means the index beat the trade.
Evans's full scored sample: 0 positive, 8 negative. Mean alpha across all 8 trades: minus 5.7 percent. The "best" trade in the set is the American Tower sale on May 11, which produced an alpha of essentially zero. The Intel sale on May 7 came in at minus 1.5 percent. Those are the top two.
The floor is rougher. The Thermo Fisher Scientific sale on May 7 clocked a 30-day alpha of minus 7.8 percent. Quanta Services that same day: minus 7.7 percent. And the Micron Technology sale back on March 24, in the $15,000-to-$50,000 range, came in at minus 14.1 percent. That's the single worst trade in the scored sample: a larger position, sold at what turned out to be exactly the wrong moment relative to the index.
To be plain about what this means: a negative alpha on a sale means the stock went up (or fell less) after Evans sold it. He sold, and the position he exited outperformed the market. Eight times in a row. The math is not flattering.
The One Trade That Has an Overlap Angle
Evans sits on the House Committee on Ways and Means, including its Health subcommittee. That's relevant to exactly one trade in the recent record.
The May 7 sale of Thermo Fisher Scientific carries a committee overlap flag. Thermo Fisher is a life sciences and healthcare instrumentation company. Healthcare is within Ways and Means Health's actual remit. Evans sold $1,000 to $15,000 worth on May 7, 2026. The 30-day alpha on that sale was minus 7.8 percent.
There are no flagged vote-trade overlaps in the data. The timing here doesn't line up with any specific vote in a way that creates a side-by-side receipt. The overlap is structural: a member who sits on a health-focused subcommittee holding and then selling a major healthcare company's stock. The interpretation of what, if anything, that means is yours to make.
The rest of his holdings, Intel, Quanta Services, American Tower, Micron, carry no committee overlap. Ways and Means handles tax, trade, and healthcare. It does not handle semiconductors, power infrastructure, or cell towers. Floor votes on unrelated legislation are floor votes. Members vote on hundreds of bills a year outside their committees.
The Votes in the Same Window
Evans voted on a flurry of financial-sector bills on May 20, all of which passed. He voted Yea on the American Access to Banking Act (H.R. 4544), the Community Bank Deposit Access Act of 2025 (H.R. 5317), and the Keeping Deposits Local Act (H.R. 3234). He also voted Yea on the 25th Anniversary of 9/11 Commemorative Coin Act.
Banking legislation sits with the House Financial Services Committee, not Ways and Means. These are floor votes, not oversight actions. There's no committee-level angle here, and the Blind Trust data flags no vote-trade overlaps from this period.
On June 25, Evans voted Yea on the Financial Exploitation Prevention Act of 2025 (H.R. 2478), which passed. On June 11, he voted Nay on a FISA extension bill (H.R. 9238), which failed. Neither vote intersects with his disclosed trades in any way the data flags.
What the Intel Sale Actually Looks Like in Context
Intel is having a rough run by any measure. Evans sold INTC on May 7 in the $1K-$15K bracket. The 30-day alpha on that sale came in at minus 1.5 percent, meaning Intel modestly underperformed the S&P 500 in the 30 days after he sold. That's the second-best outcome in his entire scored sample. His Intel timing, by the grim standards of his own record, was basically his finest hour.
The General Dynamics sale that got flagged in the Investing.com piece doesn't appear in the last-90-days disclosure window in this dataset. The broader disclosure record is available at Blind Trust's full Evans profile for anyone who wants to run the tape further back.
Members Are Required to Disclose. That's Roughly It.
The STOCK Act mandates disclosure within 45 days of a transaction. It does not require members to divest conflicting holdings, recuse themselves from relevant votes, or explain their rationale for any trade. The rule is: tell us you did it, eventually. Evans is complying with that rule. The disclosures are filed.
What the disclosures show is a congressman who has sold eight scored positions and underperformed the market on all eight, with a mean drag of 5.7 percentage points per trade, including one sale with a Ways and Means Health overlap and a worst single-trade alpha of minus 14.1 percent. The positions are small. The record is consistent.
The receipts are public. Make of them what you make of them.